• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

Meta-analysis of effectiveness and safety of proteasome inhibitor-dependent maintenance treatment for multiple myeloma a systematic review

by | Sep 18, 2024 | Publications

Heliyon. 2024 Aug 13;10(16):e36311. doi: 10.1016/j.heliyon.2024.e36311. eCollection 2024 Aug 30. ABSTRACT BACKGROUND: Even with significant advancements, treating multiple myeloma (MM) remains difficult. At present, the main treatment methods include combined...

Second primary malignancies after CAR T-cell therapy: A systematic review and meta-analysis of 5,517 lymphoma and myeloma patients

by | Sep 18, 2024 | Publications

Clin Cancer Res. 2024 Sep 11. doi: 10.1158/1078-0432.CCR-24-1798. Online ahead of print. ABSTRACT PURPOSE: CAR T-cell therapy is a potent immunotherapy for hematologic malignancies, but patients can develop long-term adverse events including second primary...

The acceptability of using wearable electronic devices to monitor physical activity of patients with Multiple Myeloma undergoing treatment: a systematic review

by | Sep 18, 2024 | Publications

Clin Hematol Int. 2024 Jul 29;6(3):38-53. doi: 10.46989/001c.121406. eCollection 2024. ABSTRACT INTRODUCTION: Multiple myeloma (MM) is diagnosed in 6,000 people in the UK yearly. A performance status measure, based on the patients’ reported level of physical...

Role of Autologous Transplant in Newly Diagnosed Multiple Myeloma Patients Treated with Novel Triplets: A Systematic Review and Meta-Analysis

by | Sep 18, 2024 | Publications

Acta Haematol. 2024 Sep 16:1-17. doi: 10.1159/000540232. Online ahead of print. ABSTRACT INTRODUCTION: High-dose therapy with melphalan followed by autologous stem cell transplant at the upfront setting (upfront ASCT) has significantly improved clinical outcomes of...

Evaluating early intervention in smoldering myeloma clinical trials: a systematic review

by | Sep 9, 2024 | Publications

Oncologist. 2024 Sep 5:oyae219. doi: 10.1093/oncolo/oyae219. Online ahead of print. ABSTRACT BACKGROUND: Smoldering multiple myeloma (SMM), an asymptomatic precursor of multiple myeloma (MM), carries a variable risk of progression to MM. There is little consensus on...

Association Between Immunoparesis and Treatment Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis

by | Aug 24, 2024 | Publications

Clin Lymphoma Myeloma Leuk. 2024 Jul 19:S2152-2650(24)00264-7. doi: 10.1016/j.clml.2024.07.008. Online ahead of print. ABSTRACT BACKGROUND: Immunoparesis, defined as suppression of uninvolved polyclonal immunoglobulins, occurs in up to 80% of patients with newly...
« Older Entries
Next Entries »

Recent Content

  • Subcutaneous Darzalex Faspro Extends PFS in Smoldering Myeloma
  • A network meta-analysis of randomized clinical trials in lenalidomide-exposed or -refractory multiple myeloma patients
  • Subcutaneous Bortezomib Associated With Reduced Incidence of Peripheral Neuropathy in Multiple Myeloma
  • Multiple Myeloma: Key Insights on Diagnosis and Evolving Treatment Strategies
  • Multiple myeloma associated long non-coding RNA PLUM confers chemoresistance by enhancing PRC2 mediated UPR pathway activation
  • Mobilization of hematopoietic stem cells using G-CSF with or without cyclophosphamide before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma receiving induction therapy with or without daratumumab
  • Incidence and prevalence of clinically detected smoldering multiple myeloma within the general population: a retrospective observational cohort study
  • The long non-coding RNA CRNDE stabilises SIRT1 protein and influences Hedgehog signalling in multiple myeloma
  • What Does Multiple Myeloma Mean?
  • FDA Update: Darzalex Faspro Not Approved for Multiple Myeloma
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT